Tue, Mar 3, 2015, 3:44 PM EST - U.S. Markets close in 16 mins.

Recent

% | $
Quotes you view appear here for quick access.

InterMune, Inc. Message Board

  • pooping_bull pooping_bull Feb 17, 2013 11:09 PM Flag

    CBO

    Any idea why CBO position was created? Is this a grooming role or is Management overwhelmed with all the marketing and supply chain issue? Mr. Nolan has an interesting background...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For some reason I can't reply to stokdude.

      One thing we've gotten from the NICE approval (which I expected would be delayed until after ASCEND reports out) is that the company can probably survive a slight failure of ASCEND. Say the primary target is met with 0.93 rather than 0.95+ significance: as long as European clinical experience continues good, there's a very decent chance that FDA would allow re-opening the trial. That's about half as long a setback as starting from scratch.

    • Best guess: rolling out a drug that needs lots of selling attention, across many markets, is a difficult project, especially if you're trying to minimize up-front costs. They wanted more experience. Backward supply chain is no big deal, but frontward supply chain (esp. keeping counterfeits off the market) in some parts of Europe is going to be challenging.

      I don't know the history of the candidates Intermune sold off in the past, but I know pirfenidone was in-licensed. It's possible that management is experienced in drug development and anxious to extend into drug discovery (finding son-of-pirfenidone) but finding drug selling orher-than-pleasant.

      Could be a farm team CEO, but I get more of the feel of a rent-a-exec.

      • 1 Reply to jacosa
      • this guy has the look of a CEO. No doubt will pay close attention to EU, which has been unremarkable to say best. Also remember, they added some commercial experience BoD members last year. Current CEO has to be tired....no doubt he expected to be done and living the high life following a US approval (and likely buyout), or a buyout post-EU approval (which they apparently screwed up). If US trial fails, its all moot anyway.....just scraps on the floor.

 
ITMN
73.89-0.02(-0.03%)Sep 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.